-
1
-
-
0028970456
-
Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
-
Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
-
(1995)
Semin Hematol
, vol.32
, pp. 45-59
-
-
Kyle, R.A.1
Gertz, M.A.2
-
2
-
-
0030895545
-
A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
-
Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207.
-
(1997)
N Engl J Med
, vol.336
, pp. 1202-1207
-
-
Kyle, R.A.1
Gertz, M.A.2
Greipp, P.R.3
Witzig, T.E.4
Lust, J.A.5
Lacy, M.Q.6
-
3
-
-
0030682237
-
Amyloidosis: A review of recent diagnostic and therapeutic developments
-
Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: A review of recent diagnostic and therapeutic developments. Br J Haematol 1997;99:245-256.
-
(1997)
Br J Haematol
, vol.99
, pp. 245-256
-
-
Gillmore, J.D.1
Hawkins, P.N.2
Pepys, M.B.3
-
4
-
-
0033630225
-
The systemic amyloidoses: An overview
-
Falk RH, Skinner M. The systemic amyloidoses: An overview. Adv Intern Med 2000;45:107-137.
-
(2000)
Adv Intern Med
, vol.45
, pp. 107-137
-
-
Falk, R.H.1
Skinner, M.2
-
5
-
-
0028936196
-
Treatment of primary amyloidosis
-
Merlini G. Treatment of primary amyloidosis. Semin Hematol 1995;32:60-79.
-
(1995)
Semin Hematol
, vol.32
, pp. 60-79
-
-
Merlini, G.1
-
6
-
-
0031913337
-
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement
-
Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-157.
-
(1998)
QJM
, vol.91
, pp. 141-157
-
-
Dubrey, S.W.1
Cha, K.2
Anderson, J.3
Chamarthi, B.4
Reisinger, J.5
Skinner, M.6
-
7
-
-
0033758844
-
Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)
-
Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26:963-969.
-
(2000)
Bone Marrow Transplant
, vol.26
, pp. 963-969
-
-
Gertz, M.A.1
Lacy, M.Q.2
Gastineau, D.A.3
Inwards, D.J.4
Chen, M.G.5
Tefferi, A.6
-
8
-
-
9144269708
-
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
-
Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004;140:85-93.
-
(2004)
Ann Intern Med
, vol.140
, pp. 85-93
-
-
Skinner, M.1
Sanchorawala, V.2
Seldin, D.C.3
Dember, L.M.4
Falk, R.H.5
Berk, J.L.6
-
9
-
-
0025884025
-
The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis
-
Wu SS, Brady K, Anderson JJ, Vezina R, Skinner M, Neiman RS, et al. The predictive value of bone marrow morphologic characteristics and immunostaining in primary (AL) amyloidosis. Am J Clin Pathol 1991;96:95-99.
-
(1991)
Am J Clin Pathol
, vol.96
, pp. 95-99
-
-
Wu, S.S.1
Brady, K.2
Anderson, J.J.3
Vezina, R.4
Skinner, M.5
Neiman, R.S.6
-
10
-
-
0344172816
-
The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients
-
Perfetti V, Colli Vignarelli M, Anesi E, Garini P, Quaglini S, Ascari E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 1999;84:218-221.
-
(1999)
Haematologica
, vol.84
, pp. 218-221
-
-
Perfetti, V.1
Colli Vignarelli, M.2
Anesi, E.3
Garini, P.4
Quaglini, S.5
Ascari, E.6
-
11
-
-
0032525180
-
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients
-
Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients. Blood 1998;91:3662-3670.
-
(1998)
Blood
, vol.91
, pp. 3662-3670
-
-
Comenzo, R.L.1
Vosburgh, E.2
Falk, R.H.3
Sanchorawala, V.4
Reisinger, J.5
Dubrey, S.6
-
12
-
-
7144251173
-
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients
-
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients. Br J Haematol 1998;101:766-769.
-
(1998)
Br J Haematol
, vol.101
, pp. 766-769
-
-
Moreau, P.1
Leblond, V.2
Bourquelot, P.3
Facon, T.4
Huynh, A.5
Caillot, D.6
-
13
-
-
0005703329
-
Symposium on amyloid cardiomyopathy: Diagnosis and treatment, Pavia, September 21, 1996
-
Merlini G. Symposium on amyloid cardiomyopathy: Diagnosis and treatment, Pavia, September 21, 1996. Amyloid 1997;4:296-299.
-
(1997)
Amyloid
, vol.4
, pp. 296-299
-
-
Merlini, G.1
|